ClinicalTrials.gov term: Primary Myelofibrosis
Myelofibrosis clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22
What changed in the last 30 days
17 trials changed in the last 30 days: 2 stopped, 9 with notable changes, 6 with minor changes only.
- Stopped: Two Step Haplo With Radiation Conditioning Recruitment suspended
- Minor: MANIFEST-3 · Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Trial sites expanded: 168 → 174 locations
- Notable: ZE74-0282 · JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders Recruitment opened
- Minor: Fedratinib · DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Trial completed
- Minor: ELRISE MF · Elritercept to Placebo · Myelofibrosis and Anemia Who Are Taking Ruxolitinib Trial sites expanded: 195 → 214 locations
- Stopped: Hu8F4 · Advanced Hematologic Malignancies Trial terminated
- Notable: cAMeLot-1 · Bleximenib · Acute Leukemia Primary completion pushed from Feb 26, 2027 to Dec 29, 2028
- Minor: ODYSSEY · Momelotinib in Combination With Luspatercept · Transfusion Dependent Myelofibrosis Study completion pushed from Mar 17, 2028 to Jan 31, 2029
- Notable: PHEMOP · Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes Primary completion pushed from Nov 19, 2026 to May 29, 2027
- Minor: PRT12396 · Select Myeloproliferative Neoplasms Trial sites expanded: 18 → 22 locations
- Notable: JAK-PeriMF · Use of Gecacitinib · Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation Recruitment opened
- Notable: Extended Access of Momelotinib · Myelofibrosis Primary endpoint(s) modified
- Notable: Selinexor and Pacritinib in JAK Inhibitor-naïve MF · Cytopenias Recruitment opened
- Minor: CLARITY-101 · DMR-001 · CALR-mutant Myeloproliferative Neoplasms Trial sites expanded: 4 → 36 locations
- Notable: Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow Primary completion pushed from Jun 2026 to Jun 2027
- Notable: Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Primary and study completion dates pushed to Feb 14, 2030
- Notable: CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors · CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Primary completion moved earlier from Jan 1, 2028 to Jan 1, 2027
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-16 | NCT07938580 Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia | Peking Union Medical College Hospital new | Phase 2 |
| 2026-11-02 | NCT07909733 Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After… | University of Wisconsin, Madison new | Phase 1 |
| 2026-10-20 | NCT07883382 An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and… | Ruijin Hospital new | Phase 1/2 |
| 2026-10-07 | NCT07863466 MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients… | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico new |
Active trials by phase
| Early Phase 1 | 3 | |
| Phase 1 | 41 | |
| Phase 1/2 | 17 | |
| Phase 2 | 43 | |
| Phase 2/3 | 1 | |
| Phase 3 | 13 | |
| Phase 4 | 2 |
Not charted: 43 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
City of Hope Medical Center (9) · Incyte Corporation (6) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (5) · M.D. Anderson Cancer Center (5) · John Mascarenhas (4) · Novartis Pharmaceuticals (4) · AbbVie (3) · Center for International Blood and Marrow Transplant Research (3) · First Affiliated Hospital of Zhejiang University (3) · Fred Hutchinson Cancer Center (3)
Get alerts when Myelofibrosis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.